Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas

doi:10.5306/wjco.v12.i10.882

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5694)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

291

WORD

170

HTML

2684

Figures (1-1)

255

Tables (1-3)

301

Sum=3701

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

360

Download

557

Sum=917

Publishing Process of This Article

Item

Count

Browse

393

Download

683

Sum=1076

Oct 24, 2021 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Oct 24, 2021; 12(10): 882-896
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.882

Open in New Tab Full Size Figure Download Figure

Figure 1 Lenalidomide mechanisms of action. IL: Interleukin; VEGF: Vascular endothelial growth factor.

Citation: Cencini E, Fabbri A, Mecacci B, Bocchia M. Role of lenalidomide in the treatment of peripheral T-cell non-Hodgkin lymphomas. World J Clin Oncol 2021; 12(10): 882-896
URL: https://www.wjgnet.com/2218-4333/full/v12/i10/882.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i10.882